VANCOUVER, BC / ACCESSWIRE / December 30, 2019 / Doubleview Capital Corp. ("Doubleview") (TSX-V:DBV) is pleased to announce it has closed the non-brokered flow-through private placement financing and proposes to close the non-flow-through private placement financing for gross proceeds of $716,000.

Non-Brokered Flow-Through Private Placement Financing

Doubleview closed the final tranche of its non-brokered flow-through private placement financing of 3,800,000 flow-through units (the "FT Units") at a price of $0.15 per Unit for gross proceeds of $570,000 (the "FT Offering"). Each FT Unit will consist of one common share to be issued as flow-through common share and one non-transferable share purchase warrant (a "Warrant"), with each Warrant exercisable at $0.15 per share for a period of two years from the date of issue.

Doubleview will have the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Doubleview's common shares is equal to, or greater than, $0.25 for 5 consecutive trading days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after Doubleview issues a news release announcing that it has elected to exercise this acceleration right.

The securities issued under the financing will be subject to a hold period expiring on December 24, 2021 pursuant to applicable Canadian securities laws and the rules of the TSX Venture Exchange.

The proceeds from the private placement will be used for exploration work on the Hat Project.

Non-Brokered Private Placement Financing

Doubleview proposes to close its non-brokered private placement financing of 1,460,000 units (the "Units") at a price of $0.10 per Unit for gross proceeds of $146,000 (the "Offering"), subject to TSX-Venture approval. Each Unit will consist of one common share and one common share purchase warrant (a "Warrant"), with each Warrant exercisable at $0.15 per share for a period of two years from the date of issue.

Doubleview will have the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Doubleview's common shares is equal to, or greater than, $0.25 for 5 consecutive trading days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after Doubleview issues a news release announcing that it has elected to exercise this acceleration right.

Hat Project Closed for the Season

Drilling at the Hat gold-copper porphyry project, with definition drilling and other exploration work ready has finished and the camp has closed for the season. The Hat Project lies within the Golden Triangle area of northwestern British Columbia, 190 kilometres south of Atlin.

About Doubleview Capital Corp.

Doubleview Capital Corp., a mineral resource exploration and development company, is based in Vancouver, British Columbia, Canada and is publicly traded on the TSX-Venture Exchange [TSX.V:DBV]. Doubleview identifies, acquires and finances precious and base metal exploration projects in North America, particularly in British Columbia, Canada. Doubleview increases shareholder value through acquisition and exploration of quality gold, copper and silver properties and the application of advanced state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.

On behalf of the Board of Directors,

Farshad Shirvani, President & Chief Executive Officer

For further information please contact:

Doubleview Capital Corp.
Suite 880, 409 Granville Street
Vancouver, BC V6C 1T2

Farshad Shirvani
President & CEO
T: (604) 678-9587
E: corporate@doubleview.ca

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Doubleview cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Doubleview's control. Such factors include, among other things: risks and uncertainties relating to Doubleview's limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Doubleview undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Doubleview Capital Corp.

ReleaseID: 571583

VAN NUYS, CA / ACCESSWIRE / December 30, 2019 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today it secured a follow-on order for a C200 Signature Series ICHP microturbine with a 20-year Factory Protection Plan (FPP) from the National Science Foundation (NSF) as part of a multi-phase modernization of the McMurdo research station with the goal of increasing energy and operational efficiency. The order was secured by Arctic Energy, Capstone's exclusive distributor in Alaska. The C200S ICHP microturbine will be delivered in 2020, and is expected to be commissioned in February 2021.

McMurdo Station is one of the three year-round Antarctic stations operated by the NSF through its Division of Polar Programs, managed by the U.S. Antarctic Program (USAP). The station serves scientists supported by the USAP and federal mission agencies such as National Oceanic and Atmospheric Administration (NOAA) and the National Aeronautics and Space Administration (NASA).

"Recorded temperature extremes have been as low as minus 50 degrees Centigrade at McMurdo, which is why their engineers continue to specify Capstone as their energy solution of choice," stated Darren Jamison, Capstone's President and Chief Executive Officer. "The reliability of Capstone's clean and green solutions in some of the most remote and harsh environments in the world makes Capstone a leading solution for customers with highly critical loads and limited infrastructure. The lack of lube oil, grease, and coolants is a huge advantage for the Capstone technology, whether it is One Vanderbilt in the middle of Manhattan or McMurdo station in Antarctica," added Mr. Jamison.

Plans to modernize the 100-building facility began in 2013 with an increased focus on reducing energy costs and carbon emissions. Capstone's innovative technology was selected for its ultra-low emissions, low maintenance, and high reliability. The C200S ICHP microturbine will run on a special jet fuel blend called AN8, unique to the Antarctic and Arctic. The new combined heat and power (CHP) system is scheduled to operate 24/7/365 in grid connect mode and projected to maximize local heat recovery usage and ensure power and heat availability for several of the buildings at the research facility.

The NSF and USAP have gone to great lengths to ensure environmental stewardship towards the modernization of the research center. The implementation of an on-site CHP Capstone microturbine will further that commitment and ensure clean and reliable power and thermal energy for the facility for years to come. The microturbine, coupled with the industry-leading 20-year FPP service contract, is expected to provide the facility with predictable and stable maintenance costs and remote monitoring capabilities at an economical price.

"This project will add to the resiliency of the existing medium voltage microgrid ring that powers McMurdo Station as they begin to utilize more distributed generation at the site," stated Greg Porter, President of Arctic Energy. "The forward-thinking approach to the NSF's upgrade of this science station is impressive in scope, and we are proud to partner with the foundation as they begin to utilize more distributed generation at this site," concluded Mr. Porter.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, providing scalable systems focusing on 30 kWs to 10 MWs that operate on a variety of gaseous or liquid fuels and are the ideal solution for today's distributed power generation needs. To date, Capstone has shipped over 9,000 units to 73 countries and has saved customers an estimated $253 million in annual energy costs and 350,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation

Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 571559

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 30, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). The BLA submission is based on the primary analysis data from the L-MIND trial of tafasitamab in combination with lenalidomide in patients with r/r DLBCL and the retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy.

"The BLA submission marks a significant milestone in MorphoSys' history and demonstrates our dedication to address the high medical need in relapsed or refractory DLBCL," said Dr. Malte Peters, Chief Development Officer of MorphoSys. "If approved, tafasitamab and lenalidomide could become an alternative treatment option for patients with this serious disease."

The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. MorphoSys will communicate the agency's decision.

About L-MIND

L-MIND is a single arm, open-label phase 2 study, investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) after up to two prior lines of therapy, including an anti-CD20 targeting therapy (e.g. rituximab), who are not eligible for high-dose chemotherapy and subsequent autologous stem cell transplantation. The study's primary endpoint is objective response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion. Primary analysis data with a cut-off date of November 30, 2018 included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year. Efficacy results in this update were based on response rates assessed by an independent review committee for all 80 patients. Based on earlier reported interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population.

About Re-MIND

Re-MIND, an observational retrospective study, was designed to isolate the contribution of tafasitamab in the combination with lenalidomide and to prove the combinatorial effect. The study compares real-world response data of patients with relapsed or refractory DLBCL who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys's L-MIND trial. Re-MIND collected the efficacy data from 490 r/r DLBCL patients in the U.S. and EU. Qualification criteria for matching patients of both studies were pre-specified. As a result, 76 eligible Re-MIND patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics. Objective response rates (ORR) were validated based on this subset of 76 patients in Re-MIND and L-MIND, respectively. The primary endpoint of Re-MIND has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.

About tafasitamab (MOR208)

Tafasitamab (MOR208) is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. Fc-modification of tafasitamab is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. Tafasitamab has been observed in preclinical models to induce direct apoptosis by binding to CD19, which is assumed to be involved in B cell receptor (BCR) signaling.

MorphoSys is clinically investigating tafasitamab as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label phase 2 combination trial (L-MIND study) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Based on interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population. Re-MIND, the real-world data lenalidomide alone matched control cohort met its primary endpoint in October 2019, demonstrating clinical superiority of the tafasitamab/lenalidomide combination compared to lenalidomide alone. The ongoing phase 3 study B-MIND assesses the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being investigated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the clinical development of tafasitamab in combination with lenalidomide in the L-MIND study in r/r DLBCL, the outcome of the Re-MIND study, the clinical development of tafasitamab in combination with bendamustine versus rituximab and bendamustine in the B-MIND study in r/r DLBCL, the further clinical development of tafasitamab as well as the BLA submission to the FDA, further interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the clinical development of tafasitamab in combination with lenalidomide in the L-MIND study in r/r DLBCL, the outcome of the Re-MIND study, the clinical development of tafasitamab in combination with bendamustine versus rituximab and bendamustine in the B-MIND study in r/r DLBCL, the further clinical development of tafasitamab as well as the BLA submission to the FDA, further interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys's Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys AG

Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
Sarah.Fakih@morphosys.com

Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
Julia.Neugebauer@morphosys.com

Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
Verena.Kupas@morphosys.com

SOURCE: MorphoSys AG

ReleaseID: 571594

LMP Automotive Holdings, Inc. Appoints Keith M. Locker to its Board of Directors

PLANTATION, FL / ACCESSWIRE / December 30, 2019 / LMP Automotive Holdings, Inc. (NASDAQ:LMPX) (the "Company" or "LMP"), an e-commerce and facilities-based platform for consumers who desire to buy, sell, rent, subscribe for or finance pre-owned and new automobiles, today announced the appointment of Keith M. Locker to its board of directors.

"On behalf of LMP and its Board of Directors, I would like to welcome Mr. Locker to the LMP team," said Sam Tawfik, the Company's Chairman and Chief Executive Officer, adding that this is perfect timing given the Company's active acquisition strategy. Mr. Locker will also bring significant capital markets expertise as LMP explores alternatives to fund the prospective acquisitions. Mr. Locker has agreed to join immediately and will be added to LMP's Audit, Compensation, and Nominating and Corporate Governance Committees.

Mr. Tawfik also added, "Keith brings significant public company directorship experience, as well as a proven track record in M&A and capital markets. He is an important and timely pedigree addition to our board of directors, given we believe we can deploy significant capital through our active pipeline of potential accretive franchise dealership acquisitions and vehicle fleet financing."

Mr. Locker stated, "I am excited and honored to work with Mr. Tawfik and the LMP board of directors. I believe my knowledge, financial expertise, public market experience and capital market relationships will facilitate execution and oversight of LMP's business strategy and add to shareholder value."

In past directorship roles, Mr. Locker has built and negotiated optimal capital structures to maximize value for stakeholders, gained deep experience in governance, risk management, and audit. He has also demonstrated a keen ability to evaluate and integrate acquisitions and portfolios.

Mr. Locker currently serves as the Chief Executive Officer and President of Inlet Capital Management LLC and serves as the President of Global Capital Resources, LLC and GCR Advisors Inc. Mr. Locker's responsibilities include overseeing all real estate capital markets activities. Mr. Locker's prior investment banking experience includes Bear, Stearns & Co. Inc., as a Senior Managing Director, and Deutsche Bank Securities, Inc., as a Managing Director.

His previous public board of directors experience include Non-Executive Chairman at Sunstone Hotel Investors, Inc. from 2011 to 2015 and as its Independent Director from 2006 until 2017, as well as an Independent Director of New York REIT, Inc., The Mills Corporation and Glenborough Realty Trust Inc.. He also served as a Director of IVP Securities, LLC.

Mr. Locker is a Trustee of National Jewish Health and Governing Trustee of Urban Land Institute and active in numerous philanthropic and community organizations. He earned an M.B.A. in Finance and Real Estate from the Wharton School of the University of Pennsylvania and a B.S./B.A. in Finance from Boston University School of Management.

About LMP Automotive Holdings, Inc. – "Buy, Rent or Subscribe, Sell and Repeat."

LMP Automotive Holdings, Inc. (NASDAQ: LMPX) describes its business model as "Buy, Rent or Subscribe, Sell and Repeat." This means that we "Buy" pre-owned automobiles primarily through auctions or directly from other automobile dealers, and new automobiles from manufacturers and manufacturer distributors at fleet rates. We "Rent or Subscribe" by either renting automobiles to our customers or allowing them to enter into our subscription plan for automobiles in which customers have use of an automobile for a minimum of thirty (30) days. LMP's all-inclusive vehicle subscription membership includes monthly swaps and covers insurance, maintenance and upkeep. It offers the flexibility to upgrade your vehicle to a more premium model or downgrade for a lesser cost model when you like. We "Sell" our inventory, including automobiles previously included in our rental and subscription programs, to customers as well, and then we "Repeat" the whole process.

Media Contact:

John Mattio
President and Founder
Lamnia International
(203) 885-1058
jmattio@lamniacom.com

For more information visit: https://lmpmotors.com/.

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "estimate," "expect," "forecast," "intend," "likely," "outlook," "plan," "potential," "project," "projection," "seek," "can," "could," "may," "should," "would," will," the negatives thereof and other words and terms of similar meanings. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: our dependence upon external sources for the financing of our operations; our ability to effectively executive our business plan; our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our services and platform; our ability to manage the growth of our operations over time; our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others; our ability to maintain relationships with existing customers and automobile suppliers, and develop relationships; and our ability to compete and succeed in a highly competitive and evolving industry; as well as other risks described in our SEC filings. There is no assurance that any forward-looking statements will materialize. You are cautioned not to place undue reliance on forward-looking statements, which reflect expectations only as of this date. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

SOURCE: LMP Automotive Holdings, Inc.

ReleaseID: 571582

WILMINGTON, DE / ACCESSWIRE / December 30, 2019 / Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against AVX Corporation (NYSE:AVX) ("AVX" or the "Company") and its Board of Directors.

If you currently own shares of AVX and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/avx-class-action-investigation/ or contact Craig J. Springer, Esq. at cspringer@andrewsspringer.com, or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook – www.facebook.com/AndrewsSpringer for future updates.

Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.

Contact:

Craig J. Springer, Esq.
cspringer@andrewsspringer.com
Toll Free: 1-800-423-6013

SOURCE: Andrews & Springer LLC

ReleaseID: 571539

MADRID, SPAIN / ACCESSWIRE / December 30, 2019 / The spanish adtech Vidoomy, whose business focus is digital video advertising, continuously develops improvements in its services and technology to continue leading the online advertising market. Vidoomy has included the users opinions who surf the Internet as part of the algorithm that they use to decide which ad is going to be shown to them.

Based on the information and results of the metrics obtained, the company filters the advertising that will be shown to users who belong to more than 2500 sites that are part of its premium inventory. This modification works so that a favorable opinion towards a product or service increases the probability that a related video ad will be displayed on the screen. Based on the same analysis, opinions or negative ratings on a service drastically reduced the options of related advertising video, since the user would not be interested. The user experience influences on what advertising users will receive during the time the are online.

Vidoomy technology uses an algorithm with associated variables that allow controlling which advertising fits better the interests of the user who will receive it and thus refine the quality of the service they offer. Until now, user opinion was not a variable that applied to these filters, but from now it is already a reality.

The work related to the technology of the company is in charge of the technical team of Vidoomy, who handles not only the developing of it but also of carrying out its improvements, like the last one added: the Vidoomy opinions filter. They have operationalized a variable that allows to increase the affinity between the advertising and the user who will receive it.

"This will really improve the experience of everyone who uses the internet every day, as of today there will be no advertising of products that do not fit the user's interests, no matter how much they are in the right target," says Eric Raventos, company COO.

On many occasions, advertising brands try to understand its target audience as a way to improve its own service, but until now the personal opinions and unique experiences of the internet user had not been used in the operational field as a way of approaching it.

"Our goal is not to be able to show the user all the possible advertising options: it is to allow the user to influence the service we offer to guarantee the result they are looking for. The formula of our success is to always take into account the priorities of our clients and the development of technological improvements such as this that allow us to carry it out," says Marcos Cuesta-CEO at Vidoomy.

http://www.vidoomy.com

Contact:
Marta Busons
Phone Number: +34 673 688 225

SOURCE: Vidoomy

ReleaseID: 571592

BALA CYNWYD, PA / ACCESSWIRE / December 30, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

ARQULE, INC. (NasdaqGS:ARQL)

Under the terms of the agreement, ArQule shareholders will receive only $20.00 for each share of ArQule common stock owned. The investigation concerns whether the ArQule Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Merck is underpaying for the Company. For example, ArQule's lead new drug candidate under development, called ARQ 531, is a potential treatment of B-cell malignancies including relapsed or refractory chronic lymphocytic leukemia. Merck's President commented, "ArQule's focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties, …. This acquisition strengthens Merck's pipeline with the addition of these strategic assets."

Additional information can be found at http://www.brodskysmith.com/cases/arqule-inc-nasdaqgs-arql/, or call 877-534-2590. No cost or obligation to you.

AUDENTES THERAPEUTICS, INC. (NasdaqGS:BOLD)

Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned. The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas Pharma, Inc.is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).

Additional information can be found at http://www.brodskysmith.com/cases/audentes-therapeutics-inc-nasdaqgs-bold/, or call 877-534-2590. No cost or obligation to you.

SYNTHORX, INC. (NasdaqGS:THOR)

Under the terms of the agreement, Synthorx shareholders will receive only $68.00 for each share of Synthorx common stock owned. The investigation concerns whether the Synthorx Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Sanofi is underpaying for the Company. For example, the drug at the center of the deal is Synthorx's investigational medicine code-named THOR-707. Meant to treat solid tumors, the drug is designed to boost the number of cancer-fighting cells in the body, potentially overwhelming the disease with effector T-cells and natural killer cells.

Additional information can be found at http://www.brodskysmith.com/cases/synthorx-inc-nasdaqgs-thor/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 571475

SUDBURY, ON / ACCESSWIRE / December 30, 2019 / Northern Superior Resources Inc. (the "Company" or "Northern Superior") (TSXV:SUP)(OTCQB:NSUPF) is very pleased to announce the addition of Mr. Michael Gentile, CFA to the Company's Board of Directors. In addition, Mr. Gentile is increasing his position in Northern Superior to 19.9 % by investing $437,000.06 in the Company in a private placement.

From 2003 to 2018 Mr. Gentile worked as a professional money manager at Formula Growth Limited, an independent investment management firm established in Montreal in 1960 with a long-term track record of creating investor wealth. While at Formula Growth Mr. Gentile's main sector focus was the mining and natural resource sectors. In 2012, he became the co-manager of the Formula Growth Alpha Fund, a market neutral hedge fund focused on small to mid-cap equities. From 2011 to 2018 the Formula Growth Alpha Fund became one of the largest market neutral funds in Canada, growing its assets under management to over $650 million by the end of 2018.

In October 2018, Mr. Gentile retired from full time money management in order to be able to spend more time with his family. Subsequently, he remains a very active investor in the mining space owning significant stakes in several small-cap mining companies and is currently a strategic advisor to Radisson Mining Resources (TSX.V RDS) and Roscan Gold Corporation (TSX.V ROS).

Mr. Gentile states: "I'm very pleased to make this major strategic investment in Northern Superior Resources and join its Board of Directors. The current dramatic undervaluation of the company, coupled with the emerging bull market in gold, makes this a compelling value proposition. Following this financing I will own a 19.9% stake in Northern Superior with warrants that will allow me to retain my percentage ownership in Northern Superior going forward."

The Company holds a large portfolio of high quality assets in Tier 1 jurisdictions (Québec and Ontario) including:

TPK – world class gold grain till anomalies, district scale land package of 47,796 hectares in a Tier 1 jurisdiction with approximately $18.5 million spent to date in moving the project forward. Discovery of eight gold-bearing shear systems during 2019 drill program, boulder assays with grades as high as 727 g/ t gold, 111g/t Ag and 4.05% Copper (see Northern Superior news release July 9, 2019), historical drilling intercepts including 28.75 g/t Au over 13.45m; and an Early Exploration Benefits Agreement with Neskantaga First Nation.
Croteau – existing Resource of 640,000 ounces gold with a cut-off grade of 1.0 g/t Au, 11.6 million tonnes, grading 1.7 g/t Au. The deposit is open at depth and along strike and offers exciting additional exploration upside with a large land package of 12,454 hectares. Recent intercepts from the 2018 drill program included 11.06 g/t gold over 9.10m (including 43.75 g/t gold over 2.00m), 61.24 g/t gold over 5.95 m (including 705 g/t gold over 0.5 m) 1.99 g/t gold over 34.65m (including 9.46 g/t gold over 2.35m) (see Northern Superior press release, August 7, 2019); and
Lac Surprise – high value exploration asset with new discoveries in late 2019 of the Épervier and the Roi gold systems adjacent to IAMGOLD/ Vanstar's Renard Deposit. They remain open along strike and depth with recent intercept of 1.54 g/t Au over 15.15m (including 10.80 g/t Au over 0.66m): indicating that the Renard deposit extends onto Northern Superior land package (see Northern Superior news release December 9, 2019).

For more in-depth information about these exceptional properties, please visit the Company's website at www.nsuperior.com.

Mr. Gentile further states: "In my opinion each of these assets alone are worth more than the current market cap of the company and in some cases potentially multiples of the current market cap."

"Northern Superior clearly has suffered from a lack of access to capital and lack of market awareness of the company's assets, I hope to assist the Northern Superior team in raising this profile and introducing the company and its assets to a wider audience of investors and strategic partners. Post financing, the Company will be well financed. Heading into 2020, the company has reduced its operating expenses by almost 10 percent from 2019 levels and continues to review the cost structure for additional savings.

"My mandate on the board will be to lead and drive a major strategic review, where the board will look at and consider all options available to unlock the significant value hidden in the mining assets of the portfolio. I look forward to assisting the Northern Superior management and board in surfacing this value for all shareholders."

Dr. T.F. Morris states: "We are very pleased to have Mr. Gentile join the Company's Board of Directors, and very grateful for his hard dollar financing. Mr. Gentile and his network of business and Corporate contacts, and those others currently working behind the scenes on behalf of the Company, represent the type of backing Northern Superior has required for some time. I am very excited at this opportunity to work with Mr. Gentile and like-minded people, who recognize the potential of Northern Superior's assets and are prepared to assist in unlocking their potential."

Private Placement

Mr. Gentile will invest $437,000.06 to subscribe for 6,242,858 units (each, a "Unit") of the Company at a subscription price of $0.07 per Unit (the "Private Placement"). Each Unit will consist of one (1) common share and one (1) non-transferable share purchase warrant (a "Warrant"). Each Warrant will entitle Mr. Gentile to purchase one (1) additional common share (each, a "Warrant Share") of the Company at an exercise price of $0.10 per Warrant Share, for a period of three (3) years. Post issuance, this Private Placement will bring Mr. Gentile's ownership to 19.9% of the Company's outstanding shares. The exercising of the warrants or purchasing of additional shares on the open market by Mr. Gentile is restricted in that Mr. Gentile's ownership must remain at no more than 19.9%, unless disinterested shareholder approval of NSUP's shareholders has first been obtained or the TSXV has otherwise waived the requirement to seek prior shareholder approval.

No commissions are payable in connection with the Private Placement.

Closing of the Private Placement is expected to occur on or before January 6, 2020. The Private Placement is subject to customary closing conditions including, but not limited to, receipt of applicable regulatory approvals, including approval of the TSX Venture Exchange.

The securities issued pursuant to the Private Placement will be subject to a four-month and one day hold period in accordance with applicable Canadian securities laws and TSX Venture Exchange policies.

About Northern Superior Resources Inc.

Northern Superior is a junior exploration company exploring for gold in the Superior Province of the Canadian Shield. The Company is currently focused on exploring its Lac Surprise, Croteau Est and Wapistan properties in Québec and its TPK property in Ontario. Northern Superior also has a number of other 100% owned properties in Ontario and Québec.

Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSX Venture Exchange under the symbol SUP.

For further information contact:

Thomas F. Morris P.Geo., PhD., FGAC
President and CEO

Tel: (705) 525 ‐0992
Fax: (705) 525 ‐7701
e‐mail: info@nsuperior.com
www.nsuperior.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statement:

Cautionary Note Regarding Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.

SOURCE: Northern Superior Resources Inc.

ReleaseID: 571495

MCLEAN, VA / ACCESSWIRE / December 30, 2019 / Cyren (NASDAQ:CYRN) today announced the appointment of Matt Mosley as Vice President of Product Management. Reporting to the CEO, Mosley will lead the execution of Cyren's product strategy and roadmap and oversee its global product management and product marketing functions.

Mosley brings nearly three decades of product experience and expertise in security operations and analytics, having previously served in senior positions at Symantec, Devo, NetIQ (acquired by Micro Focus), Internet Security Systems (acquired by IBM), Intellitactics (acquired by Trustwave), and Brabeion Software (acquired by Archer Technologies). Mosley is a frequent speaker and writer on security topics, is a member of the ISSA Global Webinar committee, and holds the CISSP, CISM, and CISA designations.

"We are fortunate to have someone with Matt's depth of product management and security experience join the Cyren executive team," said Brett Jackson, CEO of Cyren. "Matt has demonstrated over the course of his career that he is an accomplished security product thinker who delivers solutions that customers love. His product leadership will be key as Cyren continues to address emerging customer needs and delivers new products to the market."

"I am excited for the opportunity to lead Cyren's product team," Mosley said. "Cyren is uniquely positioned to protect corporations and individuals as they transition legacy email systems to the cloud and adopt next generation messaging platforms. Cyren has been a respected player in the messaging security, anti-malware, and threat intelligence markets for many years, and I look forward to bringing my experience and knowledge to the company as we create the next generation of cloud security solutions."

About Cyren

More than 1.3 billion users around the world rely on Cyren's 100% cloud security solutions to protect them against cyberattacks and data loss every day. Powered by the world's largest security cloud, Cyren (NASDAQ: CYRN) delivers fast time-to-protection with award-winning email security, cloud sandboxing and DNS filtering services for business, and threat intelligence solutions for service providers and security vendors like Microsoft, Google and Check Point. Learn more at www.cyren.com.

Blog: blog.cyren.com
Facebook: www.facebook.com/CyrenWeb
LinkedIn: www.linkedin.com/company/cyren
Twitter: www.twitter.com/CyrenInc

Company Contact:

Mike Myshrall, CFO
Cyren
+1.703.760.3320
mike.myshrall@cyren.com

Media Contact:

John Callon
Cyren
+1-650-864-2000
john.callon@cyren.com

SOURCE: Cyren

ReleaseID: 571560

NEW YORK, NY / ACCESSWIRE / December 30, 2019 / As a core IT technology, storage has gone through several evolutions: desktop storage, enterprise storage and cloud storage during 50 years' global storage industry development. Has been driven by new technology and demands, storage advancement has ushered in a new revolution milestone in an era of big data.

On Dec. 24th, YottaChain announced an exciting new: its independently researched and developed main network is launched. This achievement represents the world's first commercial public storage chain is officially launched, through which will give birth to a new industry and a new ecosystem, charting a course in a new era of blockchain storage.

With the rapid development of IT industry, China has surpassed the United States in some applications such as mobile payments. However, China still lags behind in core technology for a long time, therefore it is often constrained by others. Taking storage technology as an example, our best results are only second-class in the world.

When the wheel of history advances to the era of blockchain storage, China is bestowed with another historic opportunity to break core technology monopoly. This time, China seized the opportunity and YottaChain successfully dominated core IT technology. YottaChain not only becomes world's first public storage chain to provide commercial services to the public, but also outperforms the United States in technical architecture design and engineering implementation. The launch of Its main network marks a qualitative leap in YottaChain's development, demonstrating China has occupied the commanding heights of blockchain storage with more advanced technology, better professional technical indicators and stronger engineering implementation capabilities, which sends a message to the world that it's time for China to surpass the United States in IT core technology.

Blockchain storage is an abbreviation for Blockchain-driven WAN (Wide Area Network) storage, which means data is not stored on blockchain, but in WAN storage system. Thanks to its inherent architectural advantages, WAN storage can improve the reliability by at least 10,000 times, the availability by 100 million times compared to cloud storage, and its own luxury disaster recovery mechanism with "thousands of centers"; however, complete implementation is not easy and it is even more difficult to ensure stable operation on millions or tens of millions of edge nodes across the world. YottaChain relies on solid professional technical capabilities and strong innovation capabilities to fully demonstrate these advantages. YottaChain ensures more than a dozen storage indicators to meet commercial use requirement, with some indicators even beating existing IT giants.

In the field of blockchain storage, the most famous is IPFS from US and its incentive layer FileCoin. Its project has been developed for more than 5 years, and the public beta has just started on Dec. 15th. In comparison, YottaChain rolled out its public beta in less than a year of research and development. At present, main network has been officially released on the basis of half a year of the public beta, like a miracle.

Although the US team is well-known and heavily-financed, it lacks professional accumulation in storage and cryptography applications. Chinese team started late, but our founding team has 10-20 years of professional accumulation in storage and cryptography applications. For example, "De-TCP / IP" distributed shared storage technology surpassed the IT giants in the United States in both performance and cost. With its TruPrivacy's ciphertext deduplication technology, YottaChain has solved the world's problems that have beset cryptography and storage industries for more than a decade.

Facing the future, YottaChain will continue to take technological innovation as the core driving force, build a vigorous ecosystem as a strategic approach for commercial application landing, and enter international market with technological advantages.

YottaChain
lilySun
800-8465321
lilySun-YC@gmail.com
https://www.yottachain.io

SOURCE: YottaChain

ReleaseID: 571590